1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group Ltd.

1.78
USD
-0.02
(-1.11%)
Mar 24Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.75
0.73
0.85
1.28
1.93
2.16
2.04
2.15
2.55
2.96
3.28
3.61
4.03
- -
Basic EPS, GAAP
0.2
0.21
0.25
0.32
0.46
0.54
0.09
0.61
0.74
0.86
0.99
1.11
1.27
- -
Free Cash Flow per Basic Share
0.13
0.27
0.17
0.4
0.22
0.66
0.24
1
0.78
1.13
0.97
1.19
1.35
- -
Dividend per Share
0.24
0.04
0.03
0.12
0.2
0.08
0.27
0.16
0.25
0.16
0.41
0.83
0.59
- -
Book Value per Share
1.26
1.43
1.64
1.81
2
2.47
2.3
2.71
3.18
3.9
4.58
4.82
5.4
5.4
Tangible Book Value per Share
1.26
1.43
1.64
0.98
1.11
1.61
1.69
2.11
2.62
3.37
4.08
4.38
4.95
4.95
Basic Weighted Avg Shares
759
998
981
959
861
855
849
817
801
790
791
821
848
848
Sales/Revenue/Turnover
572
731
831
1,223
1,660
1,844
1,728
1,753
2,045
2,340
2,590
2,967
3,417
- -
Operating Margin (%)
36
32.23
35.37
32.53
32.11
35.48
32.84
31.59
31.9
30.75
31.27
32.45
33.72
- -
Depreciation Expense
13
16
19
40
67
72
73
72
73
76
78
64
67
- -
Net Income, GAAP
153
211
250
308
396
465
80
499
590
683
785
910
1,078
- -
Effective Tax Rate (%)
27.36
20.05
20.68
20.77
22.6
19.33
52.78
17.47
15.63
8.4
8.93
10.07
8.97
- -
Profit Margin (%)
26.74
28.9
30.04
25.14
23.87
25.24
4.62
28.46
28.86
29.19
30.29
30.68
31.55
- -
Working Capital
1,043
1,218
731
843
1,214
1,397
1,113
1,327
1,698
2,272
2,783
3,181
3,174
3,174
LT Debt
- -
- -
- -
- -
374
245
- -
- -
9
6
4
7
3
3
Total Equity
1,257
1,433
1,637
2,061
2,064
2,497
2,307
2,516
2,911
3,439
3,919
4,393
4,838
4,838
Return on Invested Capital (%)
18.27
15.48
16.24
16.78
17.87
18.22
2.6
16.46
17.95
18.61
19.18
20.47
22.36
- -
Return on Capital (%)
18.96
15.7
16.29
16.04
16.28
16.49
3.83
18
18.34
18.65
19.25
20.37
22.06
- -
Return on Common Equity (%)
18.96
15.7
16.27
18.1
22.6
23.84
3.85
23.67
24.4
23.7
23.17
23.57
24.98
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
260
249
210
LT Borrowings
- -
- -
- -
LT Finance Leases
7
5
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
849
850
840
Market Capitalization
6,424
6,933
- -

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
4,551
4,766
4,605
Cash, Cash Equivalents & STI
3,866
4,037
3,903
Accounts Receivable, Net
234
296
251
Inventories
290
287
271
Total Current Liabilities
1,371
1,348
1,430
Payables & Accruals
- -
- -
- -
ST Debt
260
249
210
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.85%
14%
10.13%
Free Cash Flow
56.4%
10%
16.91%
Net Income, GAAP
59.49%
16.67%
18.41%
Sales/Revenue/Turnover
16.06%
14.3%
15.17%
Total Cash Common Dividend
73.82%
50.55%
-26.77%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2,590
2024
- -
- -
2,967
2025
- -
- -
3,417

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.99
2024
- -
- -
1.11
2025
- -
- -
1.27

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.41
2024
- -
- -
0.83
2025
- -
- -
0.59

Company Description

Company Profile APIChatGPT
CEO
Meng An
Full Time Employees
3,115
Sector
Health technology
Industry
Pharmaceuticals: major
Address
71, Dongpeng Avenue Guangzhou GD China 510760
IPO Date
Dec 19, 2013
Website
chinaconsun.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Consun Pharmaceutical Group Limited (1681.HK) is a leading pharmaceutical company engaged in the research, development, manufacture, and sale of traditional Chinese medicines and healthcare products. The company offers a comprehensive portfolio of proprietary Chinese medicine products, including renowned brands such as Mailuo Shutong Pills for cardiovascular health, Xiangsha Liujun Pills for gastrointestinal disorders, Fuke Qianjin Tablets for gynecological conditions, and Compound Danshen Dripping Pills for coronary heart disease; it also provides modern healthcare products like functional foods, nutritional supplements, and medical devices targeting consumer wellness. Headquartered in Guangzhou, China, and founded in 1997, Consun operates primarily in the domestic Chinese market with distribution networks across major provinces and select international markets in Asia. Consun's business segments encompass proprietary Chinese medicines, which form the core revenue driver through branded formulations derived from classical recipes; healthcare products including herbal extracts and wellness beverages; and research-driven innovations in biotechnology pharmaceuticals. The company serves hospitals, retail pharmacies, and direct-to-consumer channels, focusing on chronic disease management and preventive healthcare for middle-aged and elderly populations. Its manufacturing facilities adhere to GMP standards, supporting large-scale production in Guangdong province. In recent developments, Consun has expanded through strategic acquisitions, including the 2024 purchase of additional stakes in key subsidiaries to consolidate its pharmaceutical pipeline, and formed alliances with research institutions for new drug development in oncology and neurology. The company launched innovative products such as upgraded bio-fermented health supplements in late 2024, alongside a major reorganization to streamline R&D operations amid regulatory changes in China's traditional medicine sector. These initiatives, coupled with a successful funding round exceeding RMB 1 billion for digital health platforms, position Consun for sustained growth in the competitive Chinese pharma landscape.